natgillin/translations-raw huggingface dataset:
Truvada can be administered in place of emtricitabine and tenofovir disoproxil used separately at the same doses.
Zdravilo Truvada se lahko jemlje namesto emtricitabina in dizoproksiltenofovirata, ki se uporabljata ločeno v enakih odmerkih.
Truvada can be used for pre-exposure prophylaxis only in individuals who have been tested to be free of HIV infection.
Za predekspozicijsko profilakso se lahko uporablja samo pri osebah, pri katerih je bila s testiranjem potrjena odsotnost okužbe z virusom HIV.
Truvada contains two active substances, emtricitabine and tenofovir disoproxil.
Zdravilo Truvada vsebuje dve zdravilni učinkovini, emtricitabin in dizoproksiltenofovirat.
Truvada contains two active substances: emtricitabine, which is a nucleoside reverse transcriptase inhibitor; and tenofovir disoproxil, which is a ‘prodrug’ of tenofovir.
Zdravilo Truvada vsebuje dve zdravilni učinkovini: emtricitabin, ki je nukleozidni zaviralec reverzne transkriptaze, in tenofovir dizoproksil, ki je „predzdravilo“ zdravila tenofovir.
Truvada does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Zdravilo Truvada ne ozdravi okužbe z virusom HIV ali aidsa, lahko pa podaljša čas do nastopa poškodb imunskega sistema in razvoja okužb ter bolezni, povezanih z aidsom.
Truvada emtricitabine / tenofovir disoproxil
Truvada emtricitabin in tenofovir dizoproksil
Truvada for PrEP:
Zdravilo Truvada za zaščito pred izpostavitvijo:
Truvada has not been studied in HIV-1 uninfected individuals with creatinine clearance < 60 mL/min and is therefore not recommended for use in this population.
Zdravilo Truvada ni bilo preučevano pri posameznikih, ki niso okuženi s HIV–1, z očistkom kreatinina < 60 ml/min in se zato ne priporoča za uporabo pri tej populaciji.
Truvada has not been studied in individuals over the age of 65.
Zdravila Truvada niso proučevali pri posameznikih, starejših od 65 let.
Truvada is also used to help prevent sexually transmitted HIV-1 infection in adults who are at high risk of being infected (‘pre-exposure prophylaxis’).
Uporablja se tudi kot pomoč za preprečevanje spolno prenosljive okužbe z virusom HIV-1 pri odraslih, pri katerih je tveganje za okužbo veliko („predekspozicijska profilaksa“).
Truvada is also used to reduce the risk of getting HIV-1 infection, when used as a daily treatment, together with safer sex practices:
Zdravilo Truvada se uporablja tudi za zmanjšanje tveganja za okužbo z virusom HIV–1, kadar se uporablja za vsakodnevno zdravljenje, ob hkratnem upoštevanju varnega spolnega vedenja:
Truvada is an antiviral medicine that contains two active substances, emtricitabine (200 mg) and tenofovir disoproxil (245 mg).
Truvada je zdravilo, ki vsebuje dve zdravilni učinkovini, emtricitabin (200 mg) in tenofovir dizoproksil (245 mg).
Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk (see sections 4.4 and 5.1).
Zdravilo Truvada je indicirano za zaščito pred izpostavitvijo, ob hkratnem upoštevanju varnega spolnega vedenja za zmanjšanje tveganja za spolno pridobljeno okužbo z virusom HIV–1 pri odraslih z visokim tveganjem (glejte poglavji 4.4 in 5.1).
Truvada is not always effective in preventing the acquisition of HIV-1.
Zdravilo Truvada ni vedno učinkovito pri preprečevanju okužbe s HIV–1.
Truvada is not for use in children and adolescents under 18 years of age.
Zdravila Truvada ne smejo uporabljati otroci in mladostniki, mlajši od 18 let.
Truvada is not recommended because appropriate dose reductions cannot be achieved with the combination tablet.
Zdravilo Truvada se ne priporoča, ker ustreznega znižanja odmerka ni mogoče doseči s kombinirano tableto.
Truvada is not recommended for use in HIV-1 uninfected individuals with
Uporaba zdravila Truvada se ne priporoča pri posameznikih, ki niso okuženi s HIV–1, s
Truvada is not recommended for use in this population.
Uporaba zdravila Truvada se pri tej populaciji ne priporoča.
Truvada is not recommended in this population (see section 4.2).
Uporaba zdravila Truvada pri tej populaciji ni priporočljiva (glejte poglavje 4.2).
Truvada is used in combination with at least one other antiviral medicine to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Zdravilo Truvada se uporablja v kombinaciji z vsaj enim drugim protivirusnim zdravilom za zdravljenje odraslih, okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
Truvada is used to treat Human Immunodeficiency Virus 1 (HIV-1) infection, in adults aged 18 years and over.
Zdravilo Truvada se uporablja za zdravljenje okužbe z virusom HIV–1 (virus človeške imunske pomanjkljivosti 1) pri odraslih, starih 18 let in več.
Truvada may affect your kidneys.
Zdravilo Truvada ima lahko vpliv na ledvice.
Truvada should always be used combined with other medicines to treat HIV infection.
Zdravilo Truvada je treba vedno uporabljati v kombinaciji z drugimi zdravili za zdravljenje okužbe z virusom HIV.
Truvada should not be administered concomitantly with adefovir dipivoxil.
Zdravila Truvada se ne sme sočasno uporabljati z dipivoksiladefoviratom.
Truvada should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil (as fumarate), tenofovir alafenamide or other cytidine analogues, such as lamivudine (see section 4.4).
Zdravila Truvada se ne sme sočasno uporabljati z drugimi zdravili, ki vsebujejo emtricitabin, dizoproksiltenofovirat (v obliki fumarata), alafenamidtenofovirat ali druge analoge citidina, kot je lamivudin (glejte poglavje 4.4).
Truvada should not be administered concomitantly with other medicinal products containing emtricitabine, tenofovir disoproxil (as fumarate), tenofovir alafenamide, or other cytidine analogues, such as lamivudine (see section 4.5).
Zdravilo Truvada se ne sme dajati skupaj z drugimi zdravili, ki vsebujejo emtricitabin, dizoproksiltenofovirat (v obliki fumarata), alafenamidtenofovirat ali druge analoge citidina, kot je lamivudin (glejte poglavje 4.5).
Truvada should only be used for pre-exposure prophylaxis as part of an overall HIV-1 infection prevention strategy including the use of other HIV-1 prevention measures (e.g. consistent and correct condom use, knowledge of HIV-1 status, regular testing for other sexually transmitted infections).
Zdravilo Truvada se sme uporabljati samo za zaščito pred izpostavitvijo kot del splošne strategije za preprečevanje okužbe s HIV–1, vključno z uporabo drugih ukrepov za preprečevanje HIV–1 (npr. dosledna in pravilna uporaba kondomov, zavedanje okužbe s HIV–1, redno testiranje za druge spolno prenosljive okužbe).
Truvada should only be used to reduce the risk of acquiring HIV-1 in individuals confirmed to be HIV negative (see section 4.3).
Zdravilo Truvada se sme uporabljati samo za zmanjšanje tveganja za okužbo s HIV–1 pri posameznikih, ki so potrjeno HIV negativni (glejte poglavje 4.3).
Truvada tablets can be disintegrated in approximately 100 mL of water, orange juice or grape juice and taken immediately.
Tableto Truvada se lahko raztopi v približno 100 ml vode, pomarančnega ali grozdnega soka.
Truvada’s active substances, taken in combination with other antiviral medicines, reduced viral loads in the majority of patients and were more effective than the comparator medicines.
Zdravilni učinkovini zdravila Truvada sta v kombinaciji z drugimi protivirusnimi zdravili znižali virusno obremenitev pri večini bolnikov in sta bili učinkovitejši kot primerjalna zdravila.
Try and space the doses evenly apart at times which are good for you – for example, first thing in the morning and then in the early evening.
Poskusite odmerke razporediti enakomerno tako, da vam bo najbolj ustrezalo – na primer zgodaj zjutraj, ko vstanete, in nato zgodaj zvečer.
Try attaching a new needle.
Poskusite pritrditi novo iglo.
Try not to breathe through your nose.
Ne poskušajte dihati skozi nos.
Try not to let the medicine touch your skin.
Pazite, da zdravilo ne pride v stik s kožo.
Try to avoid getting pregnant during treatment with Viread.
Med zdravljenjem z zdravilom Viread poskusite preprečiti nosečnost.
Try to be more physically active before you start taking the capsules.
Poskusite postati telesno bolj dejavni preden začnete jemati kapsule.
Try to be more physically active before you start taking the capsules.
Poskusite postati telesno bolj dejavni, preden začnete zdravljenje.
Try to be more physically active before you start taking the tablets.
Poskusite postati telesno bolj dejavni preden začnete jemati tablete.
Try to be more physically active before you start taking the tablets.
Poskusite postati telesno bolj dejavni, preden začnete zdravljenje.
Try to do your injection on the same day each month, to help you remember it.
Injekcijo si dajte vsak mesec na isti dan, da se boste lažje spomnili.
Try to eat frequent small meals.
Poskusite redno in pogosto uživati majhne obroke.
Try to give your injection at the same time of day.
Če je mogoče, si zdravilo injicirajte vedno ob istem času dneva.
Try to give yourself the injection at the same time each day.
Zdravilo si poskusite injicirati vedno ob istem času dneva.
Try to inject in another place in the cleaned skin area.
Poskusite injicirati v drugo vbodno mesto na očiščenem področju kože.
Try to keep to a particular day of the month to help remember your injection.
Da se lažje spomnite na injekcijo, si jo dajte na določen dan v mesecu.
try to re-use the pre-filled pen. manipulate the needle-shield before, during or after use, as this is a safety device.
poskušajte ponovno uporabiti napolnjenega injekcijskega peresnika; dotikajte se ščitnika za iglo pred, med ali po uporabi peresnika, ker je to varnostni pripomoček.
Try to reset it by following the instructions under ‘Preparing the nasal spray for use’.
Poskusite ga sprostiti po navodilih, ki so navedena pod naslovom "Priprava pršila za nos za uporabo".
Try to reset it by following the instructions under ‘Preparing the nasal spray for use’.
Poskusite jo sprostiti po navodilih, ki so navedena pod naslovom "Priprava nosnega pršila za uporabo".
Try to take a tablet at the same time each day.
Poskusite jemati tablete vsak dan ob isti uri.
Try to take a tablet at the same time each day.
Poskusite tablete jemati vsak dan ob isti uri.
Try to take it at the same time each day.
Poskušajte jemati tableto vsak dan ob istem času.
Try to take it at the same times each day.
Poskušajte jemati tableto vsak dan ob istem času.
Try to take OLYSIO at the same time each day.
Zdravilo OLYSIO poskušajte jemati vsak dan ob istem času.
Try to take the ABILIFY oral solution at the same time each day.
Prizadevajte si, da bi peroralno raztopino ABILIFY vzeli vsak dan ob istem času.
Try to take the tablet at the same time each day to help you remember.
Tableto vzemite vedno ob isti uri, da si boste lažje zapomnili.
Try to take the tablet at the same time each day.
Poskusite jemati tablete vsak dan ob isti uri.
Try to take the tablet at the same time each day.
Tablete vzemite vsak dan ob isti uri.
Try to take the tablet at the same time each day.
Tableto poskušajte vzeti vsak dan ob isti uri.
Try to take the tablet(s) at the same time every day to help you to remember it.
Najbolje je, če tableto(-e) vzamete vsak dan ob istem času, da jo (jih) ne boste pozabili vzeti.
Try to take your ABILIFY orodispersible tablets at the same time each day.
Prizadevajte si vzeti zdravilo ABILIFY orodisperzibilne tablete vsak dan ob istem času.
Try to take your ABILIFY tablets at the same time each day.
Prizadevajte si vzeti zdravilo ABILIFY tablete vsak dan ob istem času.
Try to take your Aripiprazole Mylan Pharma tablets at the same time each day.
Prizadevajte si vzeti zdravilo Aripiprazol Mylan Pharma tablete vsak dan ob istem času.
Try to take your Aripiprazole Sandoz tablets at the same time each day.
Prizadevajte si vzeti zdravilo Aripiprazol Sandoz tablete vsak dan ob istem času.
Try to take your injection at the same time of day.
Če je mogoče, si zdravilo injicirajte vedno ob istem času dneva.
try to warm the pre-filled pen by using a heat source such as hot water or microwave.
NE OGREVAJTE napolnjenega injekcijskega peresnika z virom toplote (na primer z vročo vodo ali v mikrovalovni pečici).
Try to warm the Repatha pre-filled syringe by using a heat source such as hot water or microwave.
NE OGREVAJTE napolnjene injekcijske brizge zdravila Repatha z virom toplote (na primer z vročo vodo ali v mikrovalovni pečici).
TRYPHAENA is a multicentre, randomised phase II clinical trial conducted in 225 adult female patients with HER2-positive locally advanced, operable, or inflammatory breast cancer (T2-4d; primary tumour > 2cm in diameter) who had not received prior trastuzumab, chemotherapy or radiotherapy.
TRYPHAENA je multicentrično, randomizirano, klinično preskušanje faze II pri 225 odraslih bolnicah s HER2-pozitivnim lokalno napredovalim, operabilnim ali vnetnim rakom dojk (T2–4d; primarni tumor > 2 cm v premeru), ki predhodno niso prejemale trastuzumaba, kemoterapije ali radioterapije.
Tryptose and NZ-Amines: The use of unspecified countries of origin of the cows providing the milk and unspecified suppliers of the tryptose and NZ-Amine is not considered acceptable.
Triptoza in NZ-amini: Nenavajanje držav izvora krav, od katerih je pridobljeno mleko, in nenavajanje dobaviteljev triptoze in NZ-aminov je nesprejemljivo.
TSAT change from baseline at Week 52 (mean ± SD, %)
Sprememba vrednosti
TSC1 mutations account for 20–25% of all mutations identified, and TSC2 mutations account for the remainder.
Od vseh ugotovljenih mutacij, je 20-25 % mutacij TSC1, ostale pa so mutacije TSC2.
TSH decreased
znižan TSH
TSH level must be within normal limits
Koncentracija TSH mora biti v okviru normalnih meja
TSH levels should be determined before and during the course of INCIVO combination treatment and treated as clinically appropriate, including potential adjustment of thyroid replacement therapy in patients with pre-existing hypothyroidism (see section 4.4, Laboratory tests).
Koncentracije TSH je treba določiti pred in med kombiniranim zdravljenjem z zdravilom INCIVO in ustrezno zdraviti, vključno z morebitnim prilagajanjem nadomestnega zdravljenja s ščitničnimi hormoni pri bolnikih z obstoječim hipotiroidizmom (glejte poglavje 4.4 Laboratorijske preiskave).
TSH post baseline >4 times ULN was reported in 6.9% of patients treated with Stivarga and in 0.7% of patients receiving placebo.
Poročali so, da je bil TSH glede na izhodiščno vrednost več kot štirikrat večji od zgornje normalne vrednosti pri 6,9 % bolnikov, zdravljenih z zdravilom Stivarga, in 0,7 % bolnikov, ki so prejemali placebo.
TSS Erosions JSN TSS Erosions JSN
TSS erozije JSN TSS erozije JSN
TSST- an approximation of PFS2
TSST – približek PFS2
TTO was reported in 4 cases and ranged from 0 to 30 days.
V 4 primerih so poročali o času nastopa (TTO) v razponu od 0 do 30 dni.
TTP = time to progression; "ne" indicates that it could not be estimated or it was not yet reached.
TTP = čas do napredovanja bolezni (time to progression); “no” – ni bilo mogoče oceniti ali pa še ni bilo doseženo; IZ = interval zaupanja
TTP = time to progression; "ne" indicates that it could not be estimated or it was not yet reached.
TTP = čas do napredovanja bolezni; “no” – ni bilo mogoče oceniti ali pa še ni bilo doseženo; IZ = interval zaupanja
TTP has been reported with the use of prasugrel.
Pri uporabi prasugrela so poročali o TTP.
TTP was significantly longer in the patients receiving regorafenib plus BSC than in patients receiving placebo plus BSC with a hazard ratio of 0.248 [95% CI 0.170, 0.364], and median TTP of 5.4 months versus 0.9 months (p<0.000001) (see Table 7).
TTP je bil pri bolnikih, ki so prejemali regorafenib in najboljšo podporno oskrbo, značilno daljši kot pri bolnikih, ki so prejemali placebo in najboljšo podporno oskrbo, z razmerjem ogroženosti 0,248 [95-odstotni IZ 0,170; 0,364] in mediano TTP 5,4 meseca v primerjavi z 0,9 meseci (p < 0,000001) (glejte preglednico 7).
TTP – Time to progression or death PFS – Progression-Free Survival TTF – Time to Treatment Failure
TTP: čas do napredovanja bolezni ali smrti (Time to progression or death) PFS: preživetje brez napredovanja bolezni (Progression-Free Survival) TTF: čas do neuspeha zdravljenja (Time to Treatment Failure)
TTP, days [95% CI]
(dnevi [95% CI])
TTP, days [95% CI]
TTP, dnevi [95 % CI]
TTP, months
TTP, meseci
TTP=time to progression; “ne” indicates that it could not be estimated or it was not yet reached.
ČDN = čas do napredovanja bolezni; »NO« pomeni, da ga ni bilo mogoče oceniti ali še ni dosežen.
Tubal sterilisation
Sterilizacija jajcevodov
Tubal sterilisation
terilizacija jajcevodov,
Tubal sterilisation
terilizacija jajcevodov;
Tubal sterilisation,
tubarna sterilizacija,
tube (alu)
tuba (alu)
tube (PE/Alu/PE)
Tuba (PE/Alu/PE)
tube (PE/EAA
Tuba (PE/EAA
TUBE 150 mcg/g GEL
TUBA 150 µg/g GEL
TUBE 500 mcg/g GEL
TUBA 500 µg/g GEL
Tube containing 15 g of cream
Tuba s 15 g kreme
Tuberculosis
Izločanje
tuberculosis
tuberkuloza,
tuberculosis
tuberkulozo
TUBERCULOSIS (TB) cases have been reported in patients treated with Cimzia, your doctor will check you for signs and symptoms of tuberculosis before starting Cimzia.
Ker so pri bolnikih poročali o primerih TUBERKULOZE (TB), bo vaš zdravnik pred začetkom zdravljenja z zdravilom Cimzia preveril, če imate znake in simptome tuberkuloze.
Tuberculosis (TB): You should be screened   for TB prior to ORENCIA treatment.
Tuberkuloza (TBC): Pred začetkom zdravljenja z zdravilom ORENCIA je treba izvesti presejalno testiranje za tuberkulozo.
tuberculosis and other opportunistic infections (infections that occur when resistance to disease is lowered); lung disease.
tuberkuloza in druge oportunistične okužbe (okužbe, ki se pojavijo, kadar se zmanjša odpornost proti boleznim); pljučna bolezen.
Tuberculosis can develop during therapy even if you have received preventative treatment for tuberculosis.
Tuberkuloza se lahko razvije med zdravljenjem, tudi če je vaš otrok prejel preventivno zdravljenje za tuberkulozo.
Tuberculosis can develop during therapy even if you have received treatment for the prevention of tuberculosis.
Tuberkuloza se lahko razvije med zdravljenjem, tudi če je vaš otrok prejel zdravljenje za preprečevanje tuberkuloze.
Tuberculosis has been reported in patients receiving Jakavi for MF.
Pri bolnikih, ki so prejemali zdravilo Jakavi zaradi mielofibroze, so poročali o tuberkulozi.
tuberculosis infection
okužba s tuberkulozo
tuberculosis or serious fungal infections as due to the way CELSENTRI works on certain immune cells, CELSENTRI could potentially increase the risk of developing infections.
tuberkulozo ali hudo glivično okužbo, saj lahko zdravilo CELSENTRI zaradi svojega delovanja na določene celice imunskega sistema poveča tveganje za razvoj okužb.
tuberculosis or you have been in close contact with someone who has had tuberculosis;
tuberkulozo ali ste bili v tesnem stiku z nekom, ki je imel/ima tuberkulozo;
Tuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal, viral, and other opportunistic infections have been observed in patients receiving Remicade.
Pri bolnikih, ki so prejemali zdravilo Remicade, so opažali tuberkulozo, bakterijske okužbe vključno s sepso in pljučnico, invazivne glivične, virusne in druge oportunistične okužbe.
Tuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving Humira.
Pri bolnikih, zdravljenih z zdravilom Humira so poročali o tuberkulozi, vključno z reaktivacijo in novimi pojavi tuberkuloze.
Tuberculosis: As cases of tuberculosis have been reported in patients treated with Benepali, your doctor will check for signs and symptoms of tuberculosis before starting Benepali.
Tuberkuloza: Ker so pri bolnikih, ki so se zdravili z zdravilom Benepali, poročali o primerih tuberkuloze, se bo vaš zdravnik prepričal, da nimate znakov ali simptomov tuberkuloze, preden se boste začeli zdraviti z zdravilom Benepali.
Tuberculosis: As cases of tuberculosis have been reported in patients treated with Enbrel, your doctor will check for signs and symptoms of tuberculosis before starting Enbrel.
Tuberkuloza: Ker so pri bolnikih, ki so se zdravili z zdravilom Enbrel, poročali o primerih tuberkuloze, se bo vaš zdravnik prepričal, da nimate znakov ali simptomov tuberkuloze, preden se boste začeli zdraviti z zdravilom Enbrel.
Tuberculosise
tuberkulozae
tubes
2 tubi
TUBES
TUBE
Tubular toxicity was also observed in a 2 year oral carcinogenicity study in mice at doses of 25, 75 and 150 mg/kg/day.
O toksičnih učinkih za ledvične tubule so poročali tudi pri dveletnih študijah kancerogenosti pri miših pri peroralni uporabi odmerkov 25, 75 in 150 mg/kg/dan.
Tubulointerstitial nephritis
tubulointer- sticijski nefritis
Tubulointerstitial nephritis
tubulointersticijski nefritis
tubulointerstitial nephritis
tubulointersticijski nefritis,
tubulointerstitial nephritis, renal failure
tubulointersticijski nefritis, odpoved ledvic
tubulointerstitial nephritis, renal failurea,b
tubulointersticijski nefritis, odpoved ledvica,b
Tuck flap here to close.
Če želite zapreti, spodvijte zavihek tukaj.
tudy in healthy volunteers
interakcijah pri zdravih
tudy was 50 mg when co-administered in
študiji je bil 50 mg ob sočasni uporabi s
Tue Wed Thu Fri Sat Sun
Pon Tor Sre Cet Pet Sob Ned
Tue Wed Thu Fri Sat Sun
Pon Tor Sre Čet Pet Sob Ned
Tue Wed Thu Fri Sat Sun
Tor Sre Čet Pet Sob Ned
Tue Wed Thur Fri Sat Sun
Tor Sre Čet Pet Sob Ned
Tue.
Tor.
Tuesday + Friday
torek in petek
tuffy nose
zamašen nos
tuffy nose
zamašen nos,
tuffy or runny nose
zamašen nos ali izcedek iz nosu
tuffy or runny nose
zamašen nos ali izcedek iz nosu,
tuffy or runny nose
zamašen nos ali nahod,
tuffy or runny nose
zamašen nos,
tuffy or swollen nose
zamašen ali otekel nos
Tulathromycin concentrations in lung homogenate were considerably higher than those in plasma.
V homogenizatu pljučnega tkiva je bil zaznan tulatromicin v bistveno višji
Tulathromycin is irritating to eyes.
Tulatromicin draži očesno sluznico.
Tulathromycin possesses in vitro activity against Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis, and Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumonia, Haemophilus parasuis and Bordetella bronchiseptica the bacterial pathogens most commonly associated with bovine and swine respiratory disease, respectively.
Tulatromicin izkazuje in vitro aktivnost proti Mannheimia haemolytica, Pasteurella multocida, Histophilus somni in Mycoplasma bovis ter proti Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis in Bordetella bronchiseptica to je proti patogenim bakterijam, ki so najpogostejši povzročitelji obolenj dihal pri govedu in prašičih.
Tulathromycin possesses in vitro activity against Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis, and Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica the bacterial pathogens most commonly associated with bovine and swine respiratory disease, respectively.
Tulatromicin izkazuje in vitro aktivnost proti Mannheimia haemolytica, Pasteurella multocida, Histophilus somni in Mycoplasma bovis ter proti Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis in Bordetella bronchiseptica to je proti patogenim bakterijam, ki so najpogostejši povzročitelji obolenj dihal pri govedu in prašičih.
tummy pain, indigestion
bolečina v trebuhu, prebavne težave,
tummy pain, indigestion
bolečina v trebuhu, slaba prebava,
tummy pain, indigestion,
bolečina v trebuhu, slaba prebava;
Tumor assessments were conducted every 8 weeks for the first 12 months, then every 12 weeks thereafter.
Tumorja so prvih 12 mesecev ocenjevali vsakih 8 tednov, nato pa vsakih 12 tednov.
Tumor response rate (%)
odzivnost tumorja (%)
Tumor response rate (%)
tumorja (%)